Granules India’s Revenue from operation increases by 14% to INR 411 Cr.

Mumbai, February 09, 2018: Granules India Ltd., a growing pharmaceutical manufacturing company, announced today financial results for its third quarter ended 31^st December, 2017.

            Quarterly Financial Highlights of Q3FY18

Consolidated              Margins (%)

Revenue:                    INR 411 Cr.

EBITDA:                       INR 75 Cr.                    18.2%

Net Profit:                  INR 35 Cr.                    8.5%

The Company’s standalone sales during the quarter were INR 413 Cr. In this quarter the Company recorded EBITDA and PAT of INR 78 Cr. and INR 34 Cr. respectively.

The Company’s Board of Directors has approved third interim dividend of 25 paise per share of face value of Rs. 1 each.

“Our journey towards sustainability continues as we report steady growth in our business performance. Revenue growth of 14% in the current quarter is the outcome of our investments in capacity expansion in both APIs and PFIs. However, increased cost for some of our key raw materials and forex fluctuation has impacted profit for the quarter under review. Going ahead, we are optimistic of strengthening our growth by leveraging enhanced production capacities, until our new business initiatives start contributing positively as supplementary growth drivers of the Company.” said Mr. Krishna Prasad Chigurupati, Chairman & Managing Director.

Corporate Comm India(CCI Newswire)